ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

China flag China · Delayed Price · Currency is CNY
37.26
+0.02 (0.05%)
Apr 30, 2026, 11:28 AM CST
72.73%
Market Cap 5.86B
Revenue (ttm) 801.40M
Net Income (ttm) 177.17M
Shares Out 157.39M
EPS (ttm) 1.12
PE Ratio 33.24
Forward PE 21.65
Dividend 0.06 (0.17%)
Ex-Dividend Date Nov 17, 2025
Volume 1,136,407
Average Volume 4,015,797
Open 36.80
Previous Close 37.24
Day's Range 36.80 - 37.70
52-Week Range 20.73 - 47.97
Beta 0.74
RSI 51.73
Earnings Date Apr 24, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che... [Read more]

Sector Healthcare
Founded 2001
Employees 1,450
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688117
Full Company Profile

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.46 million, an increase of 62.57% compared to the previous year's 456.07 million. Earnings were 157.92 million, an increase of 215.70%.

Financial Statements

News

There is no news available yet.